Founded in late 2020, Acelyrin has closed a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital and Westlake Village BioPartners.
Other investors joining the funding round included Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, RTW Investments, LP, Samsara BioCapital, Tybourne Capital Management and venBio Partners.
Acelyrin announced its Series A funding round in December 2020 from Westlake Village BioPartners. The company did not share the size of the fundraising round.
In related news, Los Angeles–based Acelyrin announced that Affibody AB (Stockholm, Sweden) had licensed izokibep, a late-stage IL-17A inhibitor for treating inflammatory diseases.
Izokibep is an interleukin-17A (IL-17A) inhibitor that Acelyrin believes has potential in treating several autoimmune diseases.
Acelyrin is now enrolling patients in an izokibep pivotal trial for treating uveitis, a type of inflammation within the eye. It is also enrolling for a Phase 2b trial focused on axial spondyloarthritis. The company also intends to launch a Phase 2b trial for hidradenitis suppurativa (HS), a chronic inflammatory disease involving the exocrine sweat glands.
Acelyrin plans on using the latest funding round for licensing, continuing the development of izokibep and acquiring additional programs.
The company is eyeing a potential intial public offering in 2022.
Filed Under: clinical trials, Drug Discovery
